Panomics Leadership
To enable our mission of becoming the leading provider of contextual, quantitative, systems-level measurement solutions of gene, protein and cellular function we have in place an outstanding leadership team.
With expertise in systems biology, genomic research, life science product development and general management our team brings a wealth of knowledge to Panomics allied with a track record of delivering results in previous organizations.
Frank Witney, Ph.D.
President & Chief
Executive Officer
Frank brings to Panomics 20 years of experience in leadership and innovation in the life science industry. Prior to joining Panomics, Frank was President of Drug Discovery Tools at PerkinElmer Life Sciences where he had management responsibility for the reagent and instrument businesses that included high-throughput screening, research products, genomics/proteomics and liquid handling automation. Frank assumed this position after PerkinElmer's acquisition of Packard BioScience, where previously he was President and Chief Operating Officer. At Packard, Frank was responsible for the company's global operations, including research and development, manufacturing, marketing, and worldwide sales. During his tenure, Packard achieved rapid growth in revenues and operating profits. From 1983-2000, Frank held a series of management positions at Bio-Rad Laboratories and led the company's
efforts to enter rapidly growing markets for proteomic and bioassay technologies,
most recently as Group Operations Manager of the Life Science Group. Frank
was a post-doctoral fellow at the National Institutes of Health and holds a
doctorate in molecular and cell biology from Indiana University.
TOP
TOP
George Bers
Executive Vice President, Commercial Operations
George's career in the life science industry spans 30 years and includes general
management expertise in drug discovery and clinical diagnostic product development,
marketing and sales. He has had broad experience in life science technology
and product areas, including proteomics, genomics and cellular analysis. George
has held senior management positions that include President and CEO of NuGEN
Technologies; Vice President, Systems Biology Business Center and President,
Life Science Research Division of Beckman Coulter; Vice President, Business
Development of Nanogen; and Vice President, Group Manager Clinical Diagnostics
and Vice President, Group Manager Molecular Biosystems of Bio-Rad Laboratories.
George received his BA from Duke University and an MS in Biochemistry from
Georgetown University. He is also a graduate of the Stanford Business School
Executive Management Program and has served on the Board of the Analytical
and Life Science Systems Association (ALSSA).
TOP
Gary McMaster, Ph.D.
Chief Scientific Officer
Gary brings more than 20 years of experience in drug discovery research and life science technologies to Panomics, holding senior management positions at a number of leading pharmaceutical companies. At Eli Lilly, Gary was responsible for defining and implementing the company's research technologies and systems biology programs, including the integration of novel life science technologies for the company's
target discovery research. Previously, he was Senior Director of Molecular
Biology for Pfizer, where he oversaw the application of technologies and genomics
research for drug discovery. Gary also spent 10 years at Novartis and Ciba-Geigy.
During his tenure there, he held positions of increasing responsibility including
Head of CNS Molecular and Cell Biology and Head of Neurodegenerative Diseases.
His leadership experience also includes research management positions at the
Max-Planck Institute for Immunology and Hoffman-La Roche Pharmaceuticals. Gary
received his doctorate in developmental biology from the Swiss Institute for
Experimental Cancer Research and is an author of more than 40 peer-reviewed
scientific publications and numerous world and United States patents.
TOP
Ian Ley
Vice President, Marketing
Ian joins Panomics from Beckman Coulter, having served most recently as Director
of the Cellular Analysis Research business. He has held a variety of international
sales and marketing roles of increasing seniority over the previous10 years,
gaining broad experience of general sales and marketing management, strategic
planning, and business development. Previous to Beckman Ian held various sales
positions for J.T. Baker (UK) and VG Analytical Ltd which followed time as
a part-time lecturer at the University of Central Lancashire. Ian received
his B.Sc (Hons) from Liverpool University in applied chemistry, following this
with post graduate research, focusing on retro synthetic analysis of natural
products for therapeutic use, at the University of Central Lancashire. He was
also the founder and chief consultant of the international Proficiency Testing
Scheme for laser diffraction analysis.
TOP
Yuling Luo, Ph.D.
Senior Advisor
Yuling has over 14 years of experience in life science research. Previously
Yuling is a founder and Senior Advisor to the company for functional genomics, including the b-DNA based products QuantiGene, QuantiGene Plex. In addition, Yuling is involved in developing advanced generations of bDNA products and its application to biomarker discovery. Examples of the later include gene expression analysis from formalin fixed paraffin embedded (FFPE) and blood samples.
Yuling was a Senior Scientist at Exelixis, where he led a team of scientists
to identify and validate novel therapeutic targets. Here he developed biochemical
and cell-based assays for target validation and compound screening. His expertise
encompasses nucleic acid assays, gene expression, gene regulation and mutagenesis,
protein structure-function analysis, protein engineering, and drug discovery.
Yuling has published his work in peer-reviewed journals including Cell, Neuron
and JBC. His inventions are the subject of over a dozen patents and patent
pending applications. Yuling received his doctorate in biochemistry from Case
Western Reserve University and conducted post-doctoral research at the University
of Pennsylvania.
TOP
Mark TenBoer
Vice President, Finance
Mark has over 25 years of financial management experience in a wide variety of public and private companies. Prior to joining Panomics, Mark was acting Director of Finance for Galileo Pharmaceuticals, a leader in redox pharmacology. He has extensive experience in high-growth, startup environments and has provided CFO services to Redline Networks, RightOrder, and Salira Optical Franklin Select Realty Trust, which in 1999, provided the highest total return to shareholders of all publicly traded REITs. In 2000, he was instrumental in selling the company in an all-cash transaction that distributed over $146 million to the shareholders. Mark has extensive public company experience and also has public accounting experience with Deloitte & Touche.
Mark has a bachelor's degree in Accounting from the University of Illinois,
and is a Certified Public Accountant.
TOP
Pam DeLucchi
Vice President, Operations and Quality
Pam joins Panomics from Clontech Laboratories, Inc. where she began her career in the life sciences industry 20 years ago. She initially started in R&D developing various products for the molecular biology research market. She then moved on to establishing Clontech's Manufacturing Organization, which also included Process Development and Product Transfer from R&D into Operations. In addition, Pam played a key role in Clontech's Quality Operations, helping to obtain ISO certification. Most recently, she held the role of Director of Program Management in which she was responsible for programs such as establishing a new Product Development Process and Business Integration Program post-acquisition. Pam earned her Bachelor's degree in Biology from University of California, Santa Cruz and Master's degree in Microbiology and Genetic Engineering from San Francisco State University.
TOP
Julie Xing, Ph.D.
Vice President, Asia Pacific
Julie brings more than 10 years of experience in research, clinical- and business management to Panomics. Prior to joining Panomics, Julie was the founding General Manager of Illumina China. At Illumina, Julie lead a team including sales, marketing, technical support and operations making significant contributions to the rapid growth of Illumina business in the Greater China territory. Previously, she served as clinical project manager at US AIDS Resource center in Palo Alto, California managing multiple infectious disease-related drug- and device trials. Julie's leadership experience also includes the position as CSO of Hong Kong DNA Chips Ltd., where she was responsible for product development of diagnostic kits. Julie did post-doctoral research at both Harvard University and Stanford Medical School and holds a doctorate in Biology from The Hong Kong University of Science and Technology.
TOP |
